Cardio-Vascular Events Occurring On Ponatinib In Chronic Phase Chronic Myeloid Leukemia Patients, Preliminary Analysis Of a Multicenter CohortFranck E. Nicolini, Delphine Réa, Jérémy Ruby et al.|Blood|2013Cited by 27
Analysis of Clinical Arterial and Metabolic Parameters in Chronic Phase CML Patients On Nilotinib in a Single Center CohortHélène Labussière‐Wallet, Franck E. Nicolini, Yann Guillermin et al.|Blood|2012Cited by 10
Impact Of Major Molecular Response On Overall Survival and Its Time Of Achievement On Complete Molecular Response Incidence In Chronic Myeloid Leukemia Patients Treated By Tyrosine Kinase Inhibitors In First Chronic PhaseMauricette Michallet, Xavier Thomas, Mohamad Sobh et al.|Blood|2013Cited by 1
A Significant Early Detection Of Poor Outcome In Acute Myeloid Leukemia Patients Having a Minimal Residual Disease Using Multiparameter Flow Cytomerty Combined To Mixed Chimerism At Three Months After Allogeneic Hematopoietic Stem Cell TransplantationFlorence Beckerich, Mauricette Michallet, Mohamad Sobh et al.|Blood|2013Cited by 0
MMR and CMR in Chronic Phase Chronic Myeloid Leukemia Patients: Role of Sokal Score and Different Tyrosine Kinase Inhibitors On Time of Their Obtention, Maintenance and Failure-Free SurvivalMauricette Michallet, Franck E. Nicolini, Hélène Labussière‐Wallet et al.|Blood|2012Cited by 0